Slingshot members are tracking this event:

New Data on Bristol-Myers Squibb’s Opdivo (nivolumab) Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients in Phase 2, Single-Arm Pivotal Trial

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details
Opdivo demonstrated objective response rate of 66.3% in classical Hodgkin lymphoma patients who had relapsed or progressed after auto-HSCT and subsequent brentuximab vedotin, as assessed by an independent radiologic review committee
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 10, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Nivolumab, Opdivo, Hodgkin Lymphoma, Brentuximab Vedotin